Experimental Drug Shows Promise in Preventing Pancreatic Cancer in High-Risk Patients
The story in brief
An experimental drug generated immune responses against pancreatic cancer in high-risk individuals, with none developing cancer or high-risk lesions after 16.5 months of follow-up. The phase 1 trial, conducted between April 2022 and February 2026, involved 20 participants with a hereditary predisposition and pancreatic abnormalities. KRAS mutations, common in pancreatic cancers, were targeted by the treatment, which showed mild to moderate side effects.